| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for KMDA from our risk checks.
Kamada Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪5.35 |
| 52 Week High | ₪6.53 |
| 52 Week Low | ₪4.08 |
| Beta | 0.25 |
| 11 Month Change | -3.26% |
| 3 Month Change | 1.90% |
| 1 Year Change | -0.74% |
| 33 Year Change | 0.75% |
| 5 Year Change | 1.71% |
| Change since IPO | -42.16% |
Recent News & Updates
Shareholder Returns
| KMDA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.0% | -4.0% | -4.4% |
| 1Y | -0.7% | 12.4% | 19.1% |
Return vs Industry: KMDA underperformed the US Biotechs industry which returned 12.4% over the past year.
Return vs Market: KMDA underperformed the US Market which returned 19.1% over the past year.
Price Volatility
| KMDA volatility | |
|---|---|
| KMDA Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KMDA has not had significant price volatility in the past 3 months.
Volatility Over Time: KMDA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 378 | Amir London | www.kamada.com |
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers.
Kamada Ltd. Fundamentals Summary
| KMDA fundamental statistics | |
|---|---|
| Market cap | US$314.22m |
| Earnings (TTM) | US$15.07m |
| Revenue (TTM) | US$154.57m |
20.8x
P/E Ratio2.0x
P/S RatioIs KMDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KMDA income statement (TTM) | |
|---|---|
| Revenue | US$154.57m |
| Cost of Revenue | US$89.66m |
| Gross Profit | US$64.92m |
| Other Expenses | US$49.85m |
| Earnings | US$15.07m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.26 |
| Gross Margin | 42.00% |
| Net Profit Margin | 9.75% |
| Debt/Equity Ratio | 0% |
How did KMDA perform over the long term?
See historical performance and comparison